Skip to main content
OpenTrials
Completed

NCT Number: NCT00871572

A Study for Participants With Type 2 Diabetes Mellitus

This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aschaffenburg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Participants must either be male or a female who cannot become pregnant, who has type 2 diabetes and is either controlling your diabetes through diet and exercise alone, or with diet and exercise taking metformin.
  • If participants are male, participants are willing to talk to the study doctor about birth control options during the study and for 3 months after the last dose of study medication.
  • Participants must have an Hemoglobin A1c (HbA1c) test of 6.5% to 10%
  • Participants must have a body mass index (BMI) between 25 to 40 kilograms/square meter (kg/m²).
  • Participants must be willing and able to test your blood sugar levels at home with a blood sugar meter.
  • Participants must complete a study diary as instructed by your study doctor and staff and return the study diary as instructed by the study doctor.
  • Participants must maintain consistent dietary, physical activity, and sleeping patterns throughout the study.

Exclusion criteria

  • Insulin, exenatide, or any diabetic medication other than metformin 3 months prior to screening to control you diabetes,
  • Medications to increase movement in your digestive tract or that slow movement in your digestive tract
  • Over-the-counter drugs or drugs prescribed by your doctor that cause weight loss or high or low blood sugar,
  • Chronically use oral glucocorticoids therapy or have received this type of medication within 8 weeks prior to beginning this study,
  • Class II and III antiarrhythmic agents (commonly used to prevent or relieve an irregular heartbeat),
  • Drugs that damage the liver
  • Fibrates and niacin (both commonly used to treat high cholesterol) more than 1 gram/day (gm/day),
  • Central nervous stimulants, alcohol intake for males that is more than 2 units per day and for females that is more than 1 unit per day [1 unit=12 ounces (oz) or 360 milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits].
  • You have had one (1) or more cases of uncontrolled diabetes (very high blood sugars) which required hospitalization in the 6 months prior to the screening visit or have a diagnosis of hypoglycemia (low blood sugar) unawareness.
  • You had two (2) or more emergency room visits or were hospitalized for poor control of your diabetes (for example, keto-acidotic episode) in the last 6 months.
  • Participants have a problem with your stomach such that it empties slowly (diabetic gastroparesis) or you have had gastric bypass (bariatric) surgery.
  • Participants have a personal or family history of pancreatic neoplasia.
  • Participants have abnormal lipids (for example triglycerides).
  • Participants have had problems with your heart in the past 6 months, such as a heart attack, chest pain (angina), heart failure, heart bypass operation, angioplasty (a medical procedure to open a narrow or clogged blood vessel of the heart) or stent insertion (a procedure to insert a wire mesh tube to prop open a blood vessel after angioplasty), a heart rhythm problem, or a stroke.
  • Participants have an elevated or uncontrolled blood pressure.
  • Participant's electrocardiogram (ECG, a test that measures the electrical activity of your heart) is outside the normal limits, as determined by the study doctor.
  • Participants have a problem with your kidneys or are on dialysis.
  • Participants have a problem with your pancreas.
  • Participants must not have nor had liver disease (for example, Hepatitis B or C).
  • Participants have cancer, except for skin cancer or have been in remission (the absence of disease activity) from cancer for less than 5 years.
  • Participants have a serious or uncontrolled health problems (other than type 2 diabetes), blood disorders or laboratory tests that in the opinion of the doctor, could interfere with understanding the results of this study. The doctor will let you know if this applies to you.
  • Participants previously completed or withdrew from this study or any other study investigating LY2409021.
  • Participants are allergic to the study drug or other related drugs. You cannot be in this study if you are a woman and you possibly could become pregnant during this study.

Treatment and study plan

LY2409021

Drug

4 capsules by mouth taken once daily for 12 weeks

Placebo

Drug

4 capsules by mouth once daily for 12 weeks

Primary outcomes

  1. Mean Change in Glycosylated Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 12

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was calculated using a mixed-model repeated measures analysis (MMRM) that included terms for treatment group, baseline HbA1c, metformin use, visit, and visit-by-treatment interaction.

Secondary outcomes

  1. Change From Baseline Values for Fasting Blood Glucose (FBG)

    Time frame: Baseline, Week 12

    LS mean was calculated using a MMRM that included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.

  2. Change From Baseline for Glucose Area Under the Curve (AUC) From Oral Glucose Tolerance Test (OGTT)

    Time frame: Baseline, Week 12

    LS mean was calculated using analysis of covariance (ANCOVA) model that included terms for treatment group, baseline value and metformin use.

  3. Change From Baseline to Endpoint for Fasting Triglycerides

    Time frame: Baseline, Week 12

    LS mean was calculated using ANCOVA model that included terms for treatment group, baseline value and metformin use.

  4. Total and Sub-Domain Scores of Diabetes Symptom Checklist-Revised (DSC-R)

    Time frame: Baseline, Week 12

    The DSC-R was a participant completed questionnaire that was designed to assess the presence and perceived burden of diabetes-related symptoms. Participants were asked to recall the last 4 weeks and consider each symptom/item in terms of whether they experienced it and if so, how troublesomeness it was. Participants were to consider troublesomeness of the symptom on a 1 (not at all) to 5 (extremely) point scale. There were a total of 34 items, grouped into 8 subscales: cardiovascular (4 items), psychological-cognitive distress (4 items), psychological-fatigue (4 items), hyperglycemic (4 items), hypoglycemic (3 items), neurological-pain (4 items), neurological-sensory (6 items) and visual (5 items). Sub-domain score calculated as: (sum of item scores) divided by (number of items), scores ranged from 1 to 5. Total score was the sum of all sub-domains and ranged from 8 to 40. Higher scores of total and subscales indicated worsened symptoms.

  5. Change From Baseline in the Diabetes Medicines Survey Perceived Effectiveness and Physical Side-Effects (Differences Between Perceptions About Medication-Diabetes Scores Between Placebo and LY2409021)

    Time frame: Baseline, Week 12

    The Diabetes Medicines Survey was a participant reported questionnaire consisting of 25 items: perceived effectiveness of diabetes medicines (items 1-10) and physical side-effects (items 11-25). Both domains had a scores range from 1 (all of the time) to 4 (none of the time) and a possible total scores range from 25 to 100. Lower scores for perceived effectiveness items indicated a better perceived effectiveness. Lower scores for physical side-effects items indicated a greater frequency of physical side-effects.

  6. Change From Baseline Values for 7-Point Self-Monitored Blood Glucose (SMBG) Profiles

    Time frame: Baseline, Week 12

    Participants obtained 7-point SMBG values immediately before and 2 hours after each meal and at bedtime. LS mean was calculated using a MMRM that included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.

  7. Change From Baseline Values for Fasting Insulin

    Time frame: Baseline, Week 12

    LS mean was calculated using a MMRM that included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.

  8. Change From Baseline Values for Fasting Glucagon

    Time frame: Baseline, Week 12

    LS mean was calculated using a MMRM that included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.

  9. Change From Baseline Values for Fasting Glucagon-Like Peptide 1 (GLP-1)

    Time frame: Baseline, Week 12

    LS mean was calculated using a MMRM that included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.

  10. Change From Baseline for Insulin AUC From OGTT

    Time frame: Baseline, Week 12

    LS mean was calculated using an ANCOVA that included terms for treatment group, baseline value and metformin use.

  11. Change From Baseline for C-Peptide AUC From OGTT

    Time frame: Baseline, Week 12

    LS mean was calculated using an ANCOVA model that included terms for treatment group, baseline value and metformin use.

  12. Change From Baseline to Endpoint for Low Density Lipoprotein (LDL)

    Time frame: Baseline, Week 12

    Fasting LDL LS mean was calculated using ANCOVA that included terms for baseline and treatment.

  13. Change From Baseline to Endpoint for High Density Lipoprotein (HDL)

    Time frame: Baseline, Week 12

    Fasting HDL LS mean was calculated using ANCOVA that included terms for baseline and treatment.

  14. Change From Baseline to Endpoint for Non-HDL Cholesterol

    Time frame: Baseline, Week 12

    Fasting non-HDL cholesterol LS mean was calculated using ANCOVA that included terms for baseline and treatment.

  15. Change From Baseline to Endpoint for Total Cholesterol

    Time frame: Baseline, Week 12

    Fasting total cholesterol LS mean was calculated using ANCOVA that included terms for baseline and treatment.

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of LY2409021 in Patients With Type 2 Diabetes Mellitus

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 30, 2009
Registry last updated
Apr 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.